Chloroquine Resistance in *Plasmodium falciparum* Malaria Parasites Conferred by *pfcrt* Mutations

Amar Bir Singh Sidhu, Dominik Verdier-Pinard, David A. Fidock*

Plasmodium falciparum chloroquine resistance is a major cause of worldwide increases in malaria mortality and morbidity. Recent laboratory and clinical studies have associated chloroquine resistance with point mutations in the gene *pfcrt*. However, direct proof of a causal relationship has remained elusive and most models have posited a multigenic basis of resistance. Here, we provide conclusive evidence that mutant haplotypes of the *pfcrt* gene product of Asian, African, or South American origin confer chloroquine resistance with characteristic verapamil reversibility and reduced chloroquine accumulation. *pfcrt* mutations increased susceptibility to artemisinin and quinine and minimally affected amodiaquine activity; hence, these antimalarials warrant further investigation as agents to control chloroquine-resistant *falciparum* malaria.

Chloroquine has for decades been the primary chemotherapeutic means of malaria treatment and control (1). This safe and inexpensive 4-aminoquinoline compound accumulates inside the digestive vacuole of the infected red blood cell, where it is believed to form complexes with toxic heme moieties and interfere with detoxification mechanisms that include heme sequestration into an inert pigment called hemozoin (2-4). Chloroquine resistance (CQR) was first reported in Southeast Asia and South America and has now spread to the vast majority of malaria-endemic countries (1). pfcrt was recently identified as a candidate gene for CQR after the analysis of a genetic cross between a chloroquine-resistant clone (Dd2, Indochina) and a chloroquine-sensitive clone (HB3, Honduras) (5-7). The PfCRT protein localizes to the digestive vacuole membrane and contains 10 putative transmembrane domains (7, 8). Point mutations in PfCRT, including the Lys⁷⁶ \rightarrow Thr (K76T) mutation in the first predicted transmembrane domain, show an association with CQR in field isolates and clinical studies (7, 9, 10). Episomal complementation assays demonstrated a lowlevel, atypical CQR phenotype in chloroquine-selected, transformed, pseudo-diploid parasite lines that coexpressed the Dd2 form of *pfcrt* (containing eight point mutations; Table 1), under the control of a heterologous promoter, with the wild-type endogenous allele (7).

To address whether mutations in *pfcrt* are sufficient to confer CQR, we implemented an allelic exchange approach to replace the en-

dogenous pfcrt allele of a chloroquine-sensitive line (GC03) with pfcrt alleles from chloroquine-resistant lines of Asian, African, or South American origin (Table 1) (fig. S1) (11). This approach maintained the endogenous promoter and terminator regulatory elements for correct stage-specific expression and did not use chloroquine during the selection procedure. As a result of this gene's highly interrupted nature (13 exons) and the dissemination of point mutations throughout the coding sequence, two rounds of genetic transformation were required. This enabled us to obtain pfcrt-modified clones that expressed the pfcrt allele from the chloroquineresistant lines Dd2 (clones C3^{Dd2} and C4^{Dd2}), K76I (C5^{K76I}), and 7G8 (C6^{7G8}). We also obtained the C2^{GC03} clone in which recombination had occurred downstream of the functional allele, providing a critical control in correcting for any influence of inserting the two selectable marker cassettes without exchanging *pfcrt* point mutations (Table 1) (fig. S1).

pfcrt allelic exchange was confirmed by Southern hybridization and polymerase chain reaction (PCR) analysis (fig. S2, A to D, and table S1). Reverse-transcription PCR analysis confirmed transcription of the recombinant functional pfcrt allele (fig. S2C), whereas no transcription was observed from the downstream remnant pfcrt sequences that lacked a promoter and 5' coding sequence. Western blot analysis (7, 8) revealed expression of PfCRT (about 42 kD) in all clones (fig. S2E). Quantitation analysis predicted a reduction in PfCRT expression of approximately 30 to 40%, 50%, and 0%, respectively, in the C3^{Dd2}/C4^{Dd2}. C5^{K76I}, and C6^{7G8} clones, relative to C2^{GC03}, which itself expressed 30% less PfCRT than did the original GC03 clone (11).

Phenotypic analysis showed that mutant pfcrt alleles conferred a CQR phenotype to chloroquine-sensitive P. falciparum (Fig. 1A). Recombinant clones expressing pfcrt alleles from the chloroquine-resistant lines Dd2, K76I, and 7G8 all had 50% inhibitory concentration (IC₅₀) values in the range of 100 to 150 nM. These IC₅₀ values were typically 70 to 90% of those observed with the nontransformed chloroquine-resistant lines. All these lines equaled or exceeded the 80 to 100 nM level previously proposed as a threshold diagnostic of in vivo resistant infections (12, 13). In comparison, chloroquine IC_{50} values in the recombinant control lines $C1^{GC03}$ and $C2^{GC03}$ were comparable to those observed with the initial GC03 line (20 to 30 nM). Acquisition of resistance was even more pronounced for the active metabolite monodesethylchloroquine, with IC50 values in the range of 600 to 1200 nM for the pfcrt-modified lines, versus 35 to 40 nM for chloroquine-sensitive lines (table S2).

The lower chloroquine IC550 values observed in the pfcrt-modified clones, relative to the nontransformed chloroquine-resistant lines, may be a consequence of the reduced PfCRT expression levels and other effects stemming from the complex genetic locus created in these recombinant clones (fig. S1). Alternatively, additional genetic factors might be required to attain high chloroquine IC₅₀ values. One candidate secondary determinant is *pfmdr1*, which encodes the P-glycoprotein homolog Pgh-1 that localizes to the digestive vacuole (14-16). Reed et al. (17) recently demonstrated by allelic exchange that removal of three pfmdr1 point mutations (1034C, 1042D, and 1246Y) from the 7G8 line decreased the chloroquine IC₅₀ values; however, introduction of these mutations into endogenous pfmdr1 did not alter the susceptible phenotype of a chloroquine-sensitive line. Our experiments were performed with the GC03 clone, which carries the HB3-type pfmdr1 allele that in two P. falciparum genetic crosses showed no association with decreased chloroquine susceptibility (5, 18). This allele contains the 1042D point mutation that is prevalent in chloroquine-resistant South American isolates, although this mutation does not show a consistent association with CQR in isolates from other malariaendemic regions (6, 19-21).

Acquisition of elevated chloroquine IC₅₀ values in the *pfcrt*-modified clones was accompanied by verapamil chemosensitization, a hallmark of the CQR phenotype (Fig. 1A) (22). Association of both parameters with *pfcrt* represents a marked departure from earlier suppositions that verapamil reversibility of *P. falciparum* CQR was analogous to this compound's chemosensitization of multidrug resistance in mammalian tumor cells, believed to be mediated primarily by adenosine

Department of Microbiology and Immunology, Albert Einstein College of Medicine, Bronx, NY 10461, USA.

^{*}To whom correspondence should be addressed. Email: dfidock@aecom.yu.edu

triphosphate-dependent P-glycoproteins (22). We note that verapamil reversibility was more pronounced in the clones expressing recombinant pfcrt from Old World (Dd2, K76I) origins than in the clone expressing the recombinant New World (7G8) allele. These findings are consistent with the recent report of reduced verapamil reversibility in chloroquine-resistant field isolates expressing the PfCRT 7G8 haplotype (23). In an independent confirmation of the CQR phenotype of pfcrt-modified clones, we

Fig. 1. pfcrt mutations confer chloroquine resistance and altered susceptibility to other heme (ferriprotoporphyrin IX)-binding antimalarials in P. falciparum. (A to F) Results of in vitro drug assays with pfcrt-modified and control lines. Each line was tested in duplicate against each antimalarial drug at least four times, in the presence or absence of 0.8 μ M verapamil (VP). IC_{50} values (shown as the mean + SE for each line) correspond to the concentration at which incorporation of [³H]hypoxanthine was halfmaximal and were derived from the inhibition curves generated as a function of drug concentration. Mann-Whitney tests were used to assess statistically significant differences between the reference line $C2^{GC03}$ and the others (*P < 0.05, **P < 0.01). IC₅₀ and IC₉₀ values and compound structures are detailed in table S2 and fig. S3. The finding that pfcrt mutations conferred increased susceptibility to both quinine and mefloquine provides an intriguing contrast with the recent report that the introduction of mutations into pfmdr1 led to decreased susceptibility to quinine and increased susceptibility to mefloquine (17). (G) Chloroquine accumulation assays (using 30 nM [³H]chloroquine) confirm that pfcrt mutations confer a CQR phenotype. The saturable component of [3H]chloroquine accumulation, measured as femtomoles of drug per 106 infected red blood cells, was calculated by subtracting the nonsaturable accumulation (measured in the presence of 10 µM unlabeled chloroquine) from the total accumulation (measured in the absence of unlabeled drug). The mean + SE, calculated from five experiments performed in duplicate, is shown for each line. Accumula-tion values in the *pfcrt*-modified clones $C3^{Dd2}$ and $C6^{7G8}$ showed a statistically significant difference from values observed in $C2^{GC03}$ (**P <0.01). The chloroquine data in (A) and (G) prove a central role for pfcrt point mutations in conferring CQR to the GC03 line, although they do not rule out the possibility that other loci can contribute to this phenotype. It remains to be established whether mutant pfcrt alleles can confer CQR to multiple, genetically distinct chlo-

roquine-sensitive lines. One hypothesis under consideration is that pfcrt confers CQR and altered susceptibility to other heme-binding antimalarials through a combination of direct effects (which may involve drug-protein interactions) and indirect effects on parasite physiological processes (which may influence drug accumulation and formation of drug-heme complexes).

REPORTS

observed significantly reduced [3H]chloroquine accumulation in the C3^{Dd2}, Dd2, C6^{7G8}, and 7G8 clones as compared with the chloroquinesensitive clones GC03 and C2^{GC03} (Fig. 1G). These assays measured the uptake into infected red blood cells of the saturable component of chloroquine at nanomolar concentrations, a measure that has been previously found to clearly distinguish chloroquine-resistant and chloroquine-sensitive parasites (24, 25).

Having this set of clones on the same

250

200

150

100

50

350

300

250

200

150

100

50

0

100

80

60

40

20

0

[mefloquine] (nM)

[quinine] (nM)

0

[chloroquine] (nM)

genetic background, in which CQR was produced in vitro via modification of a single gene, allowed us to begin investigations into the relationship between pfcrt, CQR, and P. falciparum susceptibility to related antimalarials. We focused initially on amodiaquine, a chloroquine analog with the same aminoquinoline ring that differs by the presence of an aromatic ring in the side chain (fig. S3). Drug assays showed that the lines harboring mutant pfcrt were slightly less susceptible to



0

30

60

Time (min)

Table 1. Transformation status and PfCRT haplotype of recombinant and wild-type lines. The first round of transformation (*11*) was performed with GCO3 and used a plasmid containing the human dihydrofolate reductase (hDHFR) selectable marker (*40*). The resulting clone, $C1^{GCO3}$ (fig. S1), shared the same chloroquine IC_{so} values (Fig. 1) (table S2) and *pfcrt* coding sequence as GCO3. Transformation of $C1^{GCO3}$ in the second round used plasmids containing the blasticidin S-deaminase (BSD) selectable marker (*41*) and resulted in the C2 to C6 clones. GCO3 is a chloroquine-sensitive progeny of the genetic cross between the chloroquine-resistant clone Dd2 (Indochina)

and the chloroquine-sensitive clone HB3 (Honduras) (5, 6). Dd2 and 7G8 (Brazil) represent common PfCRT haplotypes found in Asia/Africa and South America, respectively (7). K76I is a chloroquine-resistant line selected from the chloroquine-sensitive 106/1 (Sudan) clone propagated in the presence of high chloroquine concentrations, resulting in the generation of a full complement of PfCRT point mutations including the novel K76I mutation (8). Point mutations in boldface are those previously associated with CQR (7, 8). Abbreviations for amino acid residues: A, Ala; C, Cys; D, Asp; E, Glu; I, Ile; K, Lys; L, Leu; M, Met; N, Asn; Q, Gln; R, Arg; S, Ser; T, Thr.

Clone	First plasmid integration	Second plasmid integration	Change in PfCRT haplotype	Functional PfCRT haplotype								
				72	74	75	76	220	271	326	356	371
GC03	_			с	м	N	К	A	0	N	I	R
C1 ^{GC03}	phDHFR-crt-GC03 ^{Pf3'}	_	No	С	М	N	К	А	õ	Ν	1	R
C2 ^{GC03}	phDHFR-crt-GC03 ^{Pf3'}	pBSD-crt-Dd2 ^{Py3'}	No	С	м	N	К	А	õ	N	ł	R
C3 ^{Dd2}	phDHFR-crt-GC03 ^{Pf3'}	pBSD-crt-Dd2 ^{Pf3'}	Yes	С	1	Ε	т	S	Ē	S	т	1
C4 ^{Dd2}	phDHFR-crt-GC03 ^{Pf3'}	pBSD-crt-Dd2 ^{Py3'}	Yes	С	I	Ε	т	S	Ε	S	т	1
Dd2	·	· _	_	С	1	Ε	т	S	Ε	S	т	1
C5 ^{K76I}	phDHFR-crt-GC03 ^{Pf3'}	pBSD-crt-K76I ^{Pf3'}	Yes	С	I	Ε	1	S	Ε	S	1	1
K76I	' <u> </u>	· _	_	С	1	Ε	1	S	Ε	S	1	1
C6 ^{7G8}	phDHFR-crt-GC03 ^{Pf3'}	pBSD-crt-7G8 ^{Py3'}	Yes	S	М	Ν	т	S	0	D	L	R
7G8	· —	· _	_	S	м	N	т	S	Q	D	L	R

amodiaquine (Fig. 1B); nonetheless, the pfcrt-modified clones remained sensitive to this drug, with IC_{50} values of 22 to 36 nM. A modest degree of cross-resistance was observed between chloroquine and monodesethylamodiaquine, the primary metabolite of amodiaquine (table S2) (26-28). These findings are consistent with the published data on amodiaquine efficacy in areas with a high prevalence of CQR malaria (29, 30) and signal the need for close monitoring for resistance, including screening for possible additional changes in pfcrt sequence, with increased clinical use of amodiaquine. Further, these data suggest that CQR mediated by pfcrt point mutations now prevalent in endemic areas has a high degree of specificity for the chloroquine structure (fig. S3). Other groups have reported that altering the chloroquine side chain length can result in a gain of efficacy against chloroquine-resistant lines (31, 32).

Phenotypic characterization also revealed increased susceptibility (by a factor of 2 to 4) to quinine, mefloquine, and artemisinin and its metabolite dihydroartemisinin in the pfcrtmodified clones (Fig. 1, C, E, and F) (table S2). These data provide direct evidence for an important role for this gene in determining parasite susceptibility to these antimalarials. Collateral hypersensitivity to these compounds is reminiscent of antimalarial susceptibility patterns observed in a Thailand study of P. falciparum field isolates (33) and is encouraging given their current clinical usage in antimalarial combination therapy regimes (34). In comparison to $C2^{GC03}$, the Dd2 line is more quinine resistant; however, the introduction of the Dd2 pfcrt allele (resulting in the clones C3^{Dd2} and C4^{Dd2}) conferred quinine susceptibility (Fig. 1C). This implicates pfcrt as a component of a multifactorial process that governs parasite susceptibility to these antimalarials. Upon introduction of *pfcrt* point mutations, the increased susceptibility to quinine was accompanied by a decrease in susceptibility to the diastereomer quinidine (Fig. 1, C and D).

These data, obtained in lines that were not exposed to chloroquine pressure during their selection, agree with an earlier observation on the chloroquine-selected K76I line (7, 8) and suggest a structure-specific component of PfCRT-mediated drug accumulation in the digestive vacuole. All of these compounds are believed to act, at least in part, by complexing with heme products (35, 36). Possibly, PfCRT mutations affect accumulation by altering drug flux across the digestive vacuole membrane. Our data also document a key role for *pfcrt* point mutations in the mode of action of verapamil, a known CQR reversal agent (22, 25, 37, 38) that also chemosensitized the *pfcrt*-modified lines to quinine and quinidine (Fig. 1, C and D). This verapamilreversible phenotype may reflect a physical association between verapamil and mutant PfCRT and/or mutant PfCRT-mediated physiological changes that alter the activity of verapamil on heme processing and drughematin binding. Our genetic system now provides a direct means to evaluate the precise role of individual pfcrt point mutations in determining P. falciparum drug response and verapamil reversibility, via site-directed mutagenesis and introduction of mutant alleles into chloroquine-sensitive lines.

These data are consistent with the concept that the appearance of *pfcrt* mutant alleles in a limited number of foci was the pivotal driving force behind the genesis and spread of CQR worldwide. The structural specificity of this *pfcrt*-mediated resistance mechanism is underscored by the finding that *pfcrt*-mod-

ified clones remained susceptible to amodiaquine, promoting the use of this and related compounds that differ in their aminoquinoline side chain for the treatment of chloroquine-resistant *falciparum* malaria. Identification of PfCRT as the major component of CQR and an important determinant of susceptibility to other heme-binding antimalarials offers alternative strategies for targeting the hemoglobin detoxification pathway for malaria treatment and control.

Note added in proof: Wootton et al. (39) recently presented compelling evidence for rapid evolutionary sweeps of mutant pfcrt sequences throughout malaria-endemic areas, starting from a limited number of initial foci. These sweeps presumably occurred as a result of intense chloroquine pressure. These data complement and support our finding that mutant pfcrt sequences from different continents can confer CQR to chloroquine-sensitive parasites.

References and Notes

- 1. R. G. Ridley, Nature 415, 686 (2002).
- D. J. Sullivan Jr., H. Matile, R. G. Ridley, D. E. Goldberg, J. Biol. Chem. 273, 31103 (1998).
- S. Pagola, P. W. Stephens, D. S. Bohle, A. D. Kosar, S. K. Madsen, *Nature* 404, 307 (2000).
- H. Ginsburg, S. A. Ward, P. G. Bray, Parasitol. Today 15, 357 (1999).
- 5. T. E. Wellems et al., Nature 345, 253 (1990).
- X.-z. Su, L. S. Kirkman, T. E. Wellems, Cell 91, 593 (1997).
- 7. D. A. Fidock et al., Mol. Cell **6**, 861 (2000).
- 8. R. A. Cooper et al., Mol. Pharmacol. 61, 35 (2002).
- 9. A. Djimdé et al., N. Engl. J. Med. 344, 257 (2001).
- 10. T. E. Wellems, C. V. Plowe, J. Infect. Dis. 184, 170 (2001).
- 11. See supporting data on Science Online.
- P. Brasseur, J. Kouamouo, R. Moyou-Somo, P. Druilhe, Am. J. Trop. Med. Hyg. 46, 1 (1992).
- G. Cremer, L. K. Basco, J. Le Bras, D. Camus, C. Slomianny, *Exp. Parasitol.* 81, 1 (1995).
- S. J. Foote, J. K. Thompson, A. F. Cowman, D. J. Kemp, Cell 57, 921 (1989).
- 15. C. M. Wilson et al., Science 244, 1184 (1989).

- REPORTS
- A. F. Cowman, S. Karcz, D. Galatis, J. G. Culvenor, J. Cell Biol. 113, 1033 (1991).
- 17. M. B. Reed, K. J. Saliba, S. R. Caruana, K. Kirk, A. F. Cowman, *Nature* **403**, 906 (2000).
- M. T. Duraisingh, C. Roper, D. Walliker, D. C. Warhurst, Mol. Microbiol. 36, 955 (2000).
- S. J. Foote *et al.*, *Nature* **345**, 255 (1990).
 L. K. Basco, J. Le Bras, Z. Rhoades, C. M. Wilson, *Mol.*
- Biochem. Parasitol. 74, 157 (1995).
 21. S. C. Chaiyaroj, A. Buranakiti, P. Angkasekwinai, S. Looressuwan, A. F. Cowman, Am. J. Trop. Med. Hyg.
- 61, 780 (1999).
 22. S. K. Martin, A. M. Oduola, W. K. Milhous, *Science* 235, 899 (1987).
- 23. R. K. Mehlotra et al., Proc. Natl. Acad. Sci. U.S.A. 98, 12689 (2001).
- D. J. Krogstad, I. Y. Gluzman, B. L. Herwaldt, P. H. Schlesinger, T. E. Wellems, *Biochem. Pharmacol.* 43, 57 (1992).
- P. G. Bray, M. Mungthin, R. G. Ridley, S. A. Ward, *Mol. Pharmacol.* 54, 170 (1998).
- 26. G. E. Childs et al., Am. J. Trop. Med. Hyg. 40, 7 (1989).

- L. K. Basco, J. Le Bras, Am. J. Trop. Med. Hyg. 48, 120 (1993).
- P. G. Bray, S. R. Hawley, M. Mungthin, S. A. Ward, *Mol. Pharmacol.* 50, 1559 (1996).
- 29. P. Olliaro et al., Lancet 348, 1196 (1996).
- 30. M. Adjuik et al., Lancet 359, 1365 (2002).
- D. De, F. M. Krogstad, F. B. Cogswell, D. J. Krogstad, Am. J. Trop. Med. Hyg. 55, 579 (1996).
 R. G. Ridley et al., Antimicrob. Agents Chemother. 40,
- 1846 (1996). 33. R. N. Price et al., Antimicrob. Agents Chemother. **43**,
- 33. R. N. Price et al., Antimicrob. Agents Chemother. 4: 2943 (1999).
- 34. N. J. White, Parassitologia 41, 301 (1999).
- M. Foley, L. Tilley, *Pharmacol. Ther.* **79**, 55 (1998).
 P. M. O'Neill, P. G. Bray, S. R. Hawley, S. A. Ward, B. K. Park, *Pharmacol. Ther.* **77**, 29 (1998).
- D. J. Krogstad et al., Science 238, 1283 (1987).
 L. M. B. Ursos, S. Dzekunov, P. D. Roepe, Mol. Biochem. Parasitol. 110, 125 (2000).
- 39. J. C. Wootton et al., Nature 418, 320 (2002).
- D. A. Fidock, T. E. Wellems, Proc. Natl. Acad. Sci. U.S.A. 94, 10931 (1997).

- C. B. Mamoun, I. Y. Gluzman, S. Goyard, S. M. Beverley, D. E. Goldberg, *Proc. Natl. Acad. Sci. U.S.A.* 96, 8716 (1999).
- 42. We thank T. Wellems, P. Roepe, and S. Krishna for many helpful discussions. We also thank A. Talley, R. Cooper, D. Jacobus, S. Ward, P. Bray, W. Ellis, P. Ringwald, and N. Shulman. Supported by National Institute of Allergy and Infectious Diseases grant R01 AI50234, the Speaker's Fund for Biomedical Research, a New Scholar Award in Global Infectious Disease from the Ellison Medical Foundation, and the Howard Hughes Medical Institute Research Resources Program for Medical Schools.

Supporting Online Material

www.sciencemag.org/cgi/content/full/298/5591/210/ DC1

Materials and Methods Figs. S1 to S3

Tables S1 and S2

16 May 2002; accepted 5 August 2002

Genetic Loci Affecting Resistance to Human Malaria Parasites in a West African Mosquito Vector Population

Oumou Niaré,^{1,2}* Kyriacos Markianos,³* Jennifer Volz,⁵* Frederick Oduol,¹ Abdoulaye Touré,² Magaran Bagayoko,² Djibril Sangaré,² Sekou F. Traoré,² Rui Wang,⁵ Claudia Blass,⁵ Guimogo Dolo,² Madama Bouaré,² Fotis C. Kafatos,⁵ Leonid Kruglyak,^{3,4} Yeya T. Touré,² Kenneth D. Vernick¹†

Successful propagation of the malaria parasite *Plasmodium falciparum* within a susceptible mosquito vector is a prerequisite for the transmission of malaria. A field-based genetic analysis of the major human malaria vector, *Anopheles gambiae*, has revealed natural factors that reduce the transmission of *P. falciparum*. Differences in *P. falciparum* oocyst numbers between mosquito isofemale families fed on the same infected blood indicated a large genetic component affecting resistance to the parasite, and genome-wide scanning in pedigrees of wild mosquitoes detected segregating resistance alleles. The apparently high natural frequency of resistance alleles suggests that malaria parasites (or a similar pathogen) exert a significant selective pressure on vector populations.

Mosquitoes infected with malaria incur quantifiable costs in reproductive fitness for measures such as longevity, fecundity, and flight distance (1-3). In addition, mosquito immune

*These authors contributed equally to this work. †To whom correspondence should be addressed. Email: kenneth.vernick@nyu.edu genes respond transcriptionally to malaria parasite infection (4-6), indicating that malaria parasites are detected by mosquito immune surveillance. Inbred lines selected from mosquito colonies can inhibit parasite development through at least two distinct mechanisms: melanotic encapsulation and intracellular lysis (7, 8). Therefore, selective pressure by parasite infection could drive the natural selection of resistance mechanisms in mosquitoes. However, previous studies of resistance used laboratory strains of mosquitoes and malaria parasites, which are known to display biological aberrations in comparison to natural populations (9-11), and thus the relevance of these studies to natural malaria transmission may be questioned. Malaria resistance mechanisms and their significance for the biology of malaria transmission have not been examined previously in natural field populations of vectors.

For study of the vector-parasite interaction using field populations, standard genetic techniques that require the creation of inbred or isogenic lines were not applicable. However, the large number of progeny produced by single wild females permitted a novel study design based on isofemale pedigrees, which is quite distinct from designs previously used in human and animal genetics (fig. S1). In nature, A. gambiae females mate only once (12), and the stored sperm is used to fertilize successive egg batches that mature when the female feeds on blood. We captured pre-mated blood-fed females resting in village dwellings in Bancoumana, Mali (West Africa); allowed them to oviposit in an environmentally controlled chamber; and then raised their respective progeny in the environmental chamber (13). We used the isofemale families at either the F_1 or the F_2 stage (the latter produced by mass mating of F, mosquitoes). All females of a family were challenged with malaria parasites by being fed on blood from the same P. falciparum gametocyte carrier (14). Unfed mosquitoes were removed (15). At 8 days after infection, the progeny were dissected, and the surviving oocyst-stage parasites were counted in each midgut. The number of oocysts per mosquito constituted the quantitative infection phenotype.

We investigated the genetic dependence of mosquito resistance to malaria infection in two stages. First, in a familiality study, we compared parasite infection levels between mosquito families that were each generated by a different founding pair of wild mosquitoes. The goal was to measure interfamily differences in infection distributions, and therefore only phenotype measurements were used. Groups of three F_1 families were reared together in an environmental chamber and were fed simultaneously on blood from a

¹Department of Medical and Molecular Parasitology, New York University School of Medicine, 341 East 25th Street, New York, NY 10010, USA. ²Département d'Epidémiologie des Affectations Parasitaires, Faculté de Médecine, de Pharmacie et d'Odonto-Stomatologie, Boite Postale 1805, Barnako, Mali. ³Fred Hutchinson Cancer Research Center, 1100 Fairview Avenue North, Seattle, WA 98109, USA. ⁴Howard Hughes Medical Institute, 4000 Jones Bridge Road, Chevy Chase, MD 20815, USA. ⁵European Molecular Biology Laboratories, Meyerhofstrasse 1, 69117 Heidelberg, Germany.